By Mark G. Lebwohl MD FAAD, Warren R. Heymann MD FAAD, Ian Coulson BSc MB FRCP, Dedee Murrell MA BM MD FACD FRCP
Covering nearly 260 of the most common dermatologic conditions from A to Z, Treatment of Skin Disease, 6th Edition, by Drs. Mark G. Lebwohl, Warren R. Heymann, Ian Coulson, and Dedee Murrell, is your go-to resource for authoritative, evidence-based treatment strategies in your daily practice. This award-winning text provides guidance on the fast-moving dermatological therapy options for virtually any skin disease you’re likely to encounter, including third-line and unusual therapies when initial options have not been successful. Summaries of each treatment strategy are accompanied by detailed discussions of treatment choices, with ratings on a consistent scale ranging from clinical studies to anecdotal reports.
- Puts every possible therapeutic option at your disposal – including management strategies, first- to third-line therapies, and off-label uses – for a truly complete guide to the vast array of dermatologic treatment options.
- Features 4 all-new chapters on COVID-19 dermatoses, including the associated pediatric multisystem inflammatory syndrome; DRESS syndrome; keratosis lichenoides chronica; and tinea corporis and tinea cruris.
- Presents information in a consistent, tabular format, with checklists of diagnostic and investigative pearls and color-coded boxes for quick reference.
- Provides more than 260 full-color clinical images of skin diseases, most of which are new to this edition.
- Offers the combined knowledge and expertise of the world’s leading authorities in dermatology.
- Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.
Product Details
- Publisher : Elsevier; 6th edition (November 26, 2021)
- Language : English
- Hardcover : 964 pages
- ISBN-10 : 0702082104
- ISBN-13 : 978-0702082108
- ISBN-13 : 9780702082108
- eText ISBN: 9780702082115
Reviews
There are no reviews yet.